Medical News Hour

Mylan Inc. (NASDAQ: MYL) announced that its privately held Indian subsidiary, Matrix Laboratories Limited, has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President’s Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets, 600 mg/300 mg/300 mg.

Read more:

Mylan’s Matrix Receives Tentative FDA Approval Under PEPFAR For Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate Tablets

Related posts:

1. Shire Announces FDA Approval Of Once-Daily INTUNIV™ Extended Release Tablets For The Treatment Of ADHD In Children And Adolescents Aged 6 To 17
2. APP Pharmaceuticals Receives Approval For Deferoxamine Mesylate For Injection, USP
3. Teva Receives Final Approval For Generic Prevacid(R) Delayed-Release Capsules
4. APP Pharmaceuticals Receives Approval For The First Generic Chlorothiazide Sodium For Injection, USP
5. Reverse Medical Corporation Receives FDA IDE Clinical Study Approval For The ReStoreTM Microcatheter